Back in favour, HCQ could spur India’s Covid-19 diplomacy

Back in favour, HCQ could spur India’s Covid-19 diplomacy A global controversy regarding the drug and its efficacy as a prophylactic against Covid-19 or even as a treatment began with studies in respectable journals, the Lancet and the New England Journal of Medicine, questioning its use and hinting it could increase mortality rates among patients with a heart condition. https://ift.tt/eA8V8J